Tavlesse
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Fostamatinib
- Used in
- Blood, clotting and anaemia
- Made by
- Instituto Grifols S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (TAVALISSE). It describes the substance, not this exact product.
Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK).
The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor.
TAVALISSE is metabolized in the gut by alkaline phosphatase to the major active metabolite, R406.
Following an oral dose of TAVALISSE, approximately 80% of the R406 metabolite is excreted in feces with approximately 20% excreted in the urine.
Effect of Food Administration of TAVALISSE with a high-calorie, high-fat meal (deriving approximately 150, 250, and 500–600 calories from protein, carbohydrate, and fat, respectively) increased R406 AUC by 23% and C max by 15% [see Dosage and Administration (2.1) ].
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-05
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Instituto Grifols S.A. |
|---|---|
| Active substance | Fostamatinib |
| Used in | Blood, clotting and anaemia |
| Classification | B02BX · Blood, clotting and anaemia |
| Authorised on | 2020-01-09 |
| Last updated by the regulator | 2024-12-02 |
| EMA product number | EMEA/H/C/005012 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).